On November 19, 2026 HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces preclinical data for HMPL-A830 presented at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), held on November 18–20, 2026, in Barcelona, Spain. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate ("ATTC") drug candidate comprises a highly selective and potent KRAS small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor ("EGFR") antibody.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. While recent targeted therapies have validated KRAS (the most dominant RAS isoform) as a viable therapeutic target, significant clinical gaps remain, including safety limitations and disease progression driven by acquired resistance, often mediated by upstream receptor tyrosine kinase upregulation. HMPL-A830 is designed to address this unmet need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.
In vitro profiling demonstrated that its pan-KRAS payload exhibits a dual-action mechanism, simultaneously blocking both KRAS "ON" (GTP-RAF1 binding) and "OFF" (GDP-to-GTP exchange) activities. Potent antiproliferative activity was observed across a broad panel of 55 tumor cell lines harboring diverse KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as wild-type amplification. HMPL-A830 exhibited high binding affinity and rapid internalization into EGFR-positive cells. It also demonstrated a strong bystander killing effect, effectively eliminating neighboring EGFR-negative tumor cells, while maintaining robust antibody-dependent cellular cytotoxicity (ADCC) activity.
In mouse models, HMPL-A830 showed dose-dependent and robust antitumor efficacy across various EGFR-positive tumor models harboring KRAS alterations. HMPL-A830 achieved more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor (administered alone or in combination with cetuximab), and a TROP2-targeted Topo I-inhibitor antibody-drug conjugate. Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed a stronger and more sustained inhibition of EGFR/KRAS downstream signaling than the naked antibody, alongside a stable drug-to-antibody ratio (DAR) maintained in mouse, monkey, and human plasma.
In September 2026, HUTCHMED Limited (a subsidiary of the Company) entered into an exclusive development and license agreement with a subsidiary of GSK plc ("GSK"), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.
The Phase Ia part of an ongoing global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).
About HUTCHMED ATTCs
HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.
Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.
About KRAS
RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer ("CRC"), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma ("PDAC") patients.1 KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.
While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.
About EGFR
EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer ("NSCLC"). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.
(Press release, Hutchison China MediTech, NOV 19, 2026, View Source [SID1234674994])